Clinical stage biomedical company ProtoKinetix Incorporated (OTCMKTS:PKTX) was in the news cycle on Tuesday after it made a significant new announcement. The company revealed that it had submitted a research paper which described cell characterization, graft evaluation and yield islet like cells which could be used for the treatment and eventually lead to the cure of Type 1 diabetes.
Market Action
On Tuesday, PKTX stock ended flat at $0.0280 with more than 12.70K shares, compared to its average volume of 39.64K shares. The stock moved within a range of $0.0280 – 0.0280 after opening trade at $0.0194.
Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication
The research paper had been submitted for publication in Cell Stem Cell, a peer reviewed scientific journal that is published by Cell Press. The company also provided a copy of the paper in its press release, which could be downloaded and read by anyone who may be interested.
The paper enumerated the results that had been obtained from the currently on-going collaborative work for the optimization of stem cell produced islet transplantation. The collaboration is being led by the lab of Dr. James Shapiro, who is a renowned researcher in this particular field. The preprint of the paper is titled “Cell Characterization, Graft Evaluation, and Yield of Islet-Like Cells Differentiated From Patient-Derived iPSCs” The announcement made by the company is a significant one and if it does get published in the peer reviewed journal then it would also be a significant coup for ProtoKinetix.
 Stock Corrects After Recent Rally){kind=link}